Follow Gambro on Mynewsdesk

Latest news View all »

Gambro announced today that the U.S. Food and Drug Administration (FDA) has expanded the cleared indications for its Molecular Adsorbent Recirculating System® (MARS) to include the treatment of hepatic encephalopathy (HE) due to a decompensation of a chronic liver disease.